Work

6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates

Year: 2024

Type: article

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2024.114535

Authors: A. Hernandez, D. Urosev, J. Wong, S. Lawn, K. Wu, L. Fu, K. Stahl, M. Lasalle, D.A. Alonzo, L. Yang, A.P. Sagoe-Wagner, L. Degefie, C. Kim, A. Wu, C.W. Chen, R. Higgins, M. Petersen, R. Colombo, S.D. Barnscher, J.R. Rich

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403749020

FWCI: 0.111

Cites:

Cited by: 1

Related to: 10